- Home
- NVCT vs KINS Comparison
NVCT vs KINS Comparison
Compare NVCT & KINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVCT | KINS |
|---|---|---|
| Founded | 2020 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 205.7M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | NVCT | KINS |
|---|---|---|
| Price | $8.95 | $17.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 47.8K | ★ 118.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.17% |
| EPS Growth | N/A | ★ 94.59 |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | ★ $214,867,301.00 |
| Revenue This Year | N/A | $24.23 |
| Revenue Next Year | N/A | $18.05 |
| P/E Ratio | ★ N/A | $6.03 |
| Revenue Growth | N/A | ★ 38.50 |
| 52 Week Low | $5.55 | $13.08 |
| 52 Week High | $11.52 | $22.20 |
Technical Indicators
Market Signals| Indicator | NVCT | KINS |
|---|---|---|
| Relative Strength Index (RSI) | 58.59 | 62.43 |
| Support Level | $8.03 | $14.15 |
| Resistance Level | $9.20 | $19.42 |
| Average True Range (ATR) | 0.43 | 0.92 |
| MACD | 0.10 | 0.17 |
| Stochastic Oscillator | 80.49 | 63.23 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About KINS Kingstone Companies Inc.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.